Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780578) titled 'The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Intervention:
Drug: Andamertinib + Anlotinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 34
Countries of Recruitment:
China
T...